WuXi Biologics to manufacture NBE’s ADC for clinical trials

WuXi Biologics will manufacture NBE-Therapeutics’ lead antibody-drug conjugate, NBE-002, for use in clinical trials worldwide.

NBE-Therapeutics AG (Basel, Switzerland) plans to begin trials of the ADC in mid-2020...